DelveInsight’s “Diabetic Peripheral Neuropathy Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Diabetic Peripheral Neuropathy pipeline landscapes.
The report comprises Diabetic Peripheral Neuropathy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Diabetic Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Diabetic Peripheral Neuropathy pipeline products.
Diabetic Peripheral Neuropathy Overview
Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.
It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability.
Some of the key takeaways from the Diabetic Peripheral Neuropathy Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Helixmith, WinSanTor, Regenacy Pharmaceutical, Aptinyx, Eli Lilly and Company, Lexicon Pharmaceuticals, etc., are developing therapies for the treatment of Diabetic Peripheral Neuropathy.
-
Emerging therapies such as VM202, WST-057, Ricolinostat, NYX-2925, LY3016859, LX9211, are expected to have a significant impact on the Diabetic Peripheral Neuropathy market in the coming years.
Get an overview of pipeline landscape @ Diabetic Peripheral Neuropathy Clinical Trials Analysis
Diabetic Peripheral Neuropathy Pipeline Therapies along with Key Players:
-
VM202: Helixmith
-
WST-057: WinSanTor
-
Ricolinostat: Regenacy Pharmaceutical
-
NYX-2925: Aptinyx
-
LY3016859: Eli Lilly and Company
-
LX9211: Lexicon Pharmaceuticals
Scope of Diabetic Peripheral Neuropathy Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Helixmith, WinSanTor, Regenacy Pharmaceutical, Aptinyx, Eli Lilly and Company, Lexicon Pharmaceuticals, and others.
-
Pipeline Therapies: VM202, WST-057, Ricolinostat, NYX-2925, LY3016859, LX9211, and others.
Table of Contents
|
1 |
Diabetic Peripheral Neuropathy Report Introduction |
|
2 |
Diabetic Peripheral Neuropathy Executive Summary |
|
3 |
Diabetic Peripheral Neuropathy Overview |
|
4 |
Diabetic Peripheral Neuropathy- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Diabetic Peripheral Neuropathy Pipeline Therapeutics |
|
6 |
Diabetic Peripheral Neuropathy Late Stage Products (Phase II/III) |
|
7 |
Diabetic Peripheral Neuropathy Mid Stage Products (Phase II) |
|
8 |
Diabetic Peripheral Neuropathy Early Stage Products (Phase I) |
|
9 |
Diabetic Peripheral Neuropathy Preclinical Stage Products |
|
10 |
Diabetic Peripheral Neuropathy Therapeutics Assessment |
|
11 |
Diabetic Peripheral Neuropathy Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Diabetic Peripheral Neuropathy Key Companies |
|
14 |
Diabetic Peripheral Neuropathy Key Products |
|
15 |
Diabetic Peripheral Neuropathy Unmet Needs |
|
16 |
Diabetic Peripheral Neuropathy Market Drivers and Barriers |
|
17 |
Diabetic Peripheral Neuropathy Future Perspectives and Conclusion |
|
18 |
Diabetic Peripheral Neuropathy Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Diabetic Peripheral Neuropathy Drugs Pipeline Report.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/